Abstract Number: 0704 • ACR Convergence 2025
Human Pharmacokinetics of Inhaled Liposomal Iloprost Support a Dosing Regimen for Treating Systemic Sclerosis- Related Digital Ulcer
Background/Purpose: Iloprost is recommended and widely used in Europe for treating systemic sclerosis (SSc)-related Raynaud Phenomena (RP) and Digital Ulcer (DU). EULAR recommendation suggests continuous…Abstract Number: 0675 • ACR Convergence 2025
Neutrophil-to-Lymphocyte Ratio as a biomarker for disease onset and a predictor for mortality in Systemic Sclerosis – real-world data from a large healthcare provider in Israel.
Background/Purpose: Elevated neutrophil-to-lymphocyte ratio (NLR) in systemic sclerosis (SSc) has been demonstrated to predict worsening skin and lung involvement, and a cutoff of 2.95 was…Abstract Number: 0810 • ACR Convergence 2025
Spatial Transcriptomic-based Phenotyping of the Fibroblast Niches in Systemic Sclerosis-associated Primary Heart Involvement
Background/Purpose: Systemic sclerosis (SSc)-associated primary heart involvement (SSc-pHI) is one of the leading causes of mortality in SSc, yet its underlying cellular and molecular pathomechanisms…Abstract Number: 2652 • ACR Convergence 2025
Anti-mitochondrial antibodies in systemic sclerosis target enteric neurons and are associated with GI dysmotility
Background/Purpose: Most patients with systemic sclerosis (SSc) experience gastrointestinal (GI) dysmotility. The enteric nervous system (ENS) regulates GI motility, and its dysfunction causes dysmotility. A…Abstract Number: 2483 • ACR Convergence 2025
Is There a Seasonal Variation in Raynaud’s Phenomenon Severity in Patients with Systemic Sclerosis?
Background/Purpose: Raynaud’s phenomenon (RP) is the most common manifestation of systemic sclerosis (SSc) leading to substantial pain and impaired hand function. Establishing treatment efficacy for…Abstract Number: 1871 • ACR Convergence 2025
Examining the impact of ETV2 on altered endothelial phenotype in systemic sclerosis
Background/Purpose: Our prior research demonstrated that epigenetic modifications are central to the pathogenesis of scleroderma (SSc)1. Using ATAC-seq, we found that chromatin accessibility was significantly…Abstract Number: 1582 • ACR Convergence 2025
Risk factors for incident digital ischemic complications in systemic sclerosis in the Collaborative National Quality and Efficacy Registry (CONQUER)
Background/Purpose: There have not been large US-based studies of digital pitting scars (DPS) and digital ischemic ulcers (DIU) in systemic sclerosis. Utilizing the Collaborative National…Abstract Number: 1553 • ACR Convergence 2025
Circulating Monocyte Level Is Associated With Pulmonary Vascular Disease and Right Ventricular Dysfunction in Systemic Sclerosis
Background/Purpose: Pulmonary arterial hypertension associated with systemic sclerosis (SSc-PAH) is a life-threatening condition with obliterative pulmonary vascular remodeling, right ventricular (RV) dysfunction, and poor prognosis.…Abstract Number: 0970 • ACR Convergence 2025
Genomic instability in systemic sclerosis is promoted by metabolic remodelling via a FOXO1-dependent axis
Background/Purpose: Systemic sclerosis (SSc) is a life-threatening autoimmune disease with limited treatment options, including autologous hematopoietic stem cell transplantation (AHSCT). We recently showed that dermal…Abstract Number: 0702 • ACR Convergence 2025
Effectiveness of Oral Anticoagulants in Precapillary Pulmonary Hypertension Associated with Systemic Sclerosis: a EUSTAR Cohort Study.
Background/Purpose: Precapillary pulmonary hypertension (PH) in systemic sclerosis (SSc) associates with severe morbidity and mortality. The prothrombotic state observed in idiopathic pulmonary arterial hypertension (PAH)…Abstract Number: 0674 • ACR Convergence 2025
Quantitative Imaging in Systemic Sclerosis Patients Receiving Sodium Thiosulfate for Calcinosis Cutis
Background/Purpose: Calcinosis cutis (CC) is a disabling skin condition associated with systemic sclerosis (SSc). Although many CC treatments including sodium thiosulfate (STS) have been proposed,…Abstract Number: 0809 • ACR Convergence 2025
Human blood vessel organoids as a model of vasculopathy in systemic sclerosis
Background/Purpose: While several pathogenic processes involved in vasculopathy in systemic sclerosis (SSc) have been described1-3, the mechanisms that underlie the SSc microvasculopathy remain incompletely understood.…Abstract Number: 2555 • ACR Convergence 2025
Ergonomic Modifications: Findings From the Making it WorkTM Systemic Sclerosis Program
Background/Purpose: Work disability in people with systemic sclerosis (SS) increases substantially from diagnosis to three years after disease onset. Ergonomic modifications help people with physical,…Abstract Number: 2482 • ACR Convergence 2025
Characterizing Gastrointestinal Involvement in Systemic Sclerosis: Insights from the National Systemic sclerosis Progression INvestiGation (SPRING) Registry of the Italian Society of Rheumatology
Background/Purpose: Gastrointestinal (GI) involvement affects over 80% of patients with systemic sclerosis (SSc), contributing significantly to morbidity and representing the third leading cause of disease-related…Abstract Number: 1868 • ACR Convergence 2025
Global Downregulation of Fli1 in Mice Induces Cardiac Dysfunction via Enhanced β-fatty acid Oxidation and Collagen Deposition
Background/Purpose: Primary cardiac involvement is a common complication of Systemic sclerosis (SSc), characterized by fibrosis and diastolic dysfunction, presumably due to microvascular dysfunction and repeated…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 56
- Next Page »